On February 17, 2022, Roche Diagnostics China (hereinafter referred to as "Roche") announced in Shanghai that it had reached a strategic partnership with Sanomede Medical Technology Co., Ltd. (hereinafter referred to as "Sanomede") to jointly launch a new RS600 Lab Automation System (LAS) for Chinese market. The cooperation between the two sides takes expanding the supply of high-quality medical resources as the starting point. By integrating the advantages of technical resources, the two sides provide more efficient, flexible and economical automation solutions for laboratory medicine, so as to help the continuous improvement of China's overall medical service level and benefit the general public.

It is reported that RS600 integrates loading and unloading units, saves laboratory space layout, and optimizes sample turnover path by using two-way four track design. Equipped with radio frequency identification (RFID) technology and high-speed "chain plate" technology, RS600 can quickly and accurately identify samples, and the track speed is up to 3600 tubes / hour. RS600 is suitable for Roche Cobas series analyzer, including biochemical, immune, hemagglutination and other modules to ensure the accuracy of test results. In addition, Roche will also provide original after-sales services, including "one-stop" services such as professional assembly line service team, overall laboratory solutions and whole laboratory design.

Xie Zhimin, Deputy Secretary General of Changchun Municipal Government, Secretary of the Party Working Committee of the Economic Development Zone Secretary, director of the management committee, said: "Promoting the expansion and balanced distribution of high-quality medical resources and promoting the equalization of basic medical and health services are important measures to effectively solve the problem of medical treatment for the people. We are glad to see that Roche together with Sanomede actively responded to the call of "healthy China", jointly launched LAS to meet the needs of China's diversified national conditions, contributed to the capacity-building of grass-roots medical and health services, and enabled more people to enjoy world-class medical services. "

Talking about this cooperation, Yao Guoliang, General manager of Roche said: "In recent years, through strategic cooperation, the company has actively explored innovative business models with local excellent enterprises and jointly promoted the construction of an integrated ecosystem of diagnosis and treatment. Working with Sanomede to build an RS600 LAS is another innovative exploration of Roche in cooperation with local excellent enterprises. It is hoped that the launch of RS600 can fill the market gap and meet different medical needs. The demand of health institutions for diversified and high-quality diagnostic programs will further improve the overall medical service capacity, improve people's medical experience and health level, and benefit Chinese patients. "

Sun Chengxin, general manager of Sanomede, said: "As a pioneer enterprise in the domestic independent research and development of LAS, Sanomede has been committed to the in-depth research and development in the field of laboratory automation. It is a great honor to become a strategic partner with Roche, the global leader of in vitro diagnosis, bring richer and diversified overall laboratory solutions to the Chinese market, and contribute to the vigorous development and development of laboratory medicine in China."

Roche and Sanomede integrate the world's leading technology to customize the RS600 LAS for Chinese laboratories. By integrating accurate and reliable testing technology and flexible and diverse layout schemes. Roche and Sanomede can optimize the workflow to the greatest extent, ensure the testing quality, control the operating cost, and solve the problems of standardization problems in detection efficiency and operation management.